Essential Thrombocythemia in Children: A Retrospective Study

Background

Essential thrombocythemia (ET) is one of the “classic” Philadelphia chromosome negative (Ph-) myeloproliferative neoplasms characterized by sustained thrombocytosis, increased megakaryopoiesis and high risk of vascular complications. ET is very rare in childhood. The annual incidence is approximately 1 per 10,000,000 in children less than 14 years, and about 60 times lower than adults. The genetic landscape and clonal features in childhood ET has not been well defined. There is no evidence-based guidance on the diagnosis of childhood ET.

Methods

Medical records of 28 pediatric patients (age ≤ 14 years at diagnosis) with ET were reviewed and evaluated to characterize the different mutation profiles and to evaluate the treatment modalities used and the potential long-term outcome.

Results

More than half of the patients were found to have positive history of parental consanguinity (57.1%) whereas positive family history was documented for more than a quarter of our patients (28.6%). Janus kinase 2 gene (JAK2) V617F mutation was positive in two of 26 patients (7.7%). Myeloproliferative leukemia virus oncogene (MPL) exon 10 and calreticulin (CALR) mutations were tested in eight patients, which were negative for all of them. Treatment included low-dose aspirin (LDA) in seven patients (50%), combination of LDA with hydroxyurea in three patients (21.4%), hydroxyurea in two patients (14.3%), combination of platelets apheresis with LDA and anagrelide in one patient each (7.1%). During the treatment, two patients experienced stroke (7.1%), one patient developed Budd-Chiari syndrome (3.6%) and one patient developed azoospermia (3.6%).

Conclusions

The incidence of ET in children is extremely low in Saudi Arabia. Most of the children with ET were asymptomatic, and thrombocytosis was often discovered incidentally. JAK2 V617F mutation has no known impact on the prognosis or on the outcome of the disease in the pediatric age group that is in contrast to the adult ET. Children less than 1 year are at high risk for complications particularly during acute precipitating infectious episode. The potential complications and clinical course of pediatric ET are unpredictable.

^{Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia}

^{Corresponding Author: Abdulrahman Al-Musa, Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. Email:}as.ude.crhsfk@asuma

Received 2021 Mar 28; Accepted 2021 Apr 17.

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Methods

Results

Conclusions

Keywords: Essential thrombocythemia, Pediatric ET, JAK2 mutation

Abstract

Acknowledgments

None to declare.

Acknowledgments

References

1. Cervantes FManagement of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2011;2011:215–221. doi: 10.1182/asheducation-2011.1.215.] [[PubMed][Google Scholar]
2. Hasle HIncidence of essential thrombocythaemia in children. Br J Haematol. 2000;110(3):751. doi: 10.1046/j.1365-2141.2000.02239-7.x.] [[PubMed][Google Scholar]
3. Barbui THow to manage children and young adults with myeloproliferative neoplasms. Leukemia. 2012;26(7):1452–1457. doi: 10.1038/leu.2012.12.] [[PubMed][Google Scholar]
4. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G. et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007;25(9):1048–1053. doi: 10.1200/JCO.2006.08.6884.] [[PubMed]
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061. doi: 10.1016/S0140-6736(05)71142-9.] [[PubMed]
6. Ismael O, Shimada A, Hama A, Sakaguchi H, Doisaki S, Muramatsu H, Yoshida N. et al. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children. Pediatr Blood Cancer. 2012;59(3):530–535. doi: 10.1002/pbc.23409.] [[PubMed]
7. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi: 10.1038/nature03546.] [[PubMed]
8. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–3476. doi: 10.1182/blood-2006-04-018879.] [[PubMed]
9. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi: 10.1371/journal.pmed.0030270.] [
10. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi: 10.1056/NEJMoa1311347.] [[PubMed]
11. Tefferi A, Pardanani AMyeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015;1(1):97–105. doi: 10.1001/jamaoncol.2015.89.] [[PubMed][Google Scholar]
12. Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi AThe 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev. 2016;30(6):453–459. doi: 10.1016/j.blre.2016.06.001.] [[PubMed][Google Scholar]
13. Kvasnicka HM, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP. et al. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017;92(10):1062–1067. doi: 10.1002/ajh.24837.] [[PubMed]
14. Randi ML, Putti MC, Scapin M, Pacquola E, Tucci F, Micalizzi C, Zanesco L. et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood. 2006;108(10):3600–3602. doi: 10.1182/blood-2006-04-014746.] [[PubMed]
15. Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola A, Mazzucconi MG. et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10):2219–2227. doi: 10.1182/blood-2011-08-371328.] [[PubMed]
16. Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T. et al. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Pediatr Blood Cancer. 2008;51(6):802–805. doi: 10.1002/pbc.21730.] [[PubMed]
17. Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC, Bosch A. et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218–1223. doi: 10.1038/sj.leu.2404693.] [[PubMed]
18. Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z. et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97(1):109–121. doi: 10.1007/s00277-017-3165-9.] [[PubMed]
19. Awada H, Voso MT, Guglielmelli P, Gurnari CEssential thrombocythemia and acquired von Willebrand Syndrome: the shadowlands between thrombosis and bleeding. 2020;12(7):1746. doi: 10.3390/cancers12071746. Published 2020 Jun 30. ] [